This is what analysts have to say about Affimed N.V. (NASDAQ:AFMD) after last week.

November 10, 2018 - By Marguerite Chambers

Affimed N.V. (NASDAQ:AFMD) Ratings Coverage

Among 2 analysts covering Affimed (NASDAQ:AFMD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Affimed had 3 analyst reports since August 9, 2018 according to SRatingsIntel. The rating was upgraded by Jefferies on Tuesday, August 28 to “Buy”. BMO Capital Markets maintained the stock with “Outperform” rating in Tuesday, August 28 report. The rating was maintained by BMO Capital Markets on Thursday, August 9 with “Outperform”. Below is a list of Affimed N.V. (NASDAQ:AFMD) latest ratings and price target changes.

28/08/2018 Broker: Jefferies Old Rating: Hold New Rating: Buy Old Target: $1.8 New Target: $4 Upgrade
28/08/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $4 New Target: $5 Maintain
09/08/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $6 New Target: $4 Maintain

The stock decreased 3.79% or $0.16 during the last trading session, reaching $4.06. About 845,659 shares traded. Affimed N.V. (NASDAQ:AFMD) has risen 126.19% since November 10, 2017 and is uptrending. It has outperformed by 110.57% the S&P500.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $253.46 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More notable recent Affimed N.V. (NASDAQ:AFMD) news were published by: Globenewswire.com which released: “Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress” on November 07, 2018, also Globenewswire.com with their article: “Affimed to Present at the Jefferies 2018 London Healthcare Conference” published on November 08, 2018, Seekingalpha.com published: “Affimed Therapeutics 2018 Q3 – Results – Earnings Call Slides” on November 07, 2018. More interesting news about Affimed N.V. (NASDAQ:AFMD) were released by: Seekingalpha.com and their article: “Affimed Therapeutics (AFMD) CEO Adi Hoess on Q3 2018 Results – Earnings Call Transcript” published on November 07, 2018 as well as Nasdaq.com‘s news article titled: “Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology …” with publication date: November 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>